Ruxing Wu1, Fei Liu2, Ping Peng2, Hong Qiu2, Huihua Xiong2, Shiying Yu2, Xiaoyuan Huang1, Hanwang Zhang1, Liang Zhuang2. 1. Reproductive Medicine Center, Department of Obstetrics and Gynecology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. 2. Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract
BACKGROUND: Recent studies suggested an important relationship between tumor stress-induced phosphoprotein 1 (STIP1) and cancer. However, the expression of STIP1 in breast cancer tissues and its relationship with clinical characteristics and survival have not been investigated in humans. The aim of our work was to evaluate the association of STIP1 and the prognosis of breast cancer patients. METHODS: The included patients were followed-up by telephone and through a review of their outpatient records. The expression of STIP1 was assessed by immunohistochemistry (IHC). The 5-year recurrence-free survival (RFS) rate and the 5-year overall survival (OS) rate were the prognostic indicators evaluated by the Kaplan-Meier method. Univariate and multivariate analyses employing a Cox regression model were used to calculate hazard ratios (HRs). RESULTS: The rate of high expression of STIP1 was 55.3% (126/228) in breast cancer tissues and 14.9% (34/228) in adjacent normal tissues (χ2=81.495, P<0.001). High expression of STIP1 was associated with tumor size, stage and human epidermal growth factor receptor 2 (HER-2) status. The 5-year RFS rate was 75.4% in the STIP1 high expression group and 87.3% in the STIP1 low expression group (χ2=5.721, P=0.017). The 5-year OS rate was 84.1% in the STIP1 high expression group and 94.1% in the STIP1 low expression group (χ2=5.814, P=0.016). STIP1 was found to be an independent relapse predictor for the adjusted HR is 1.983 (95% CI, 1.031-3.815). CONCLUSIONS: High expression of STIP1 is associated with the poor prognosis of breast cancer patients and HER-2 positive expression. STIP1 may therefore serve as a prognostic biomarker for breast cancer patients.
BACKGROUND: Recent studies suggested an important relationship between tumor stress-induced phosphoprotein 1 (STIP1) and cancer. However, the expression of STIP1 in breast cancer tissues and its relationship with clinical characteristics and survival have not been investigated in humans. The aim of our work was to evaluate the association of STIP1 and the prognosis of breast cancer patients. METHODS: The included patients were followed-up by telephone and through a review of their outpatient records. The expression of STIP1 was assessed by immunohistochemistry (IHC). The 5-year recurrence-free survival (RFS) rate and the 5-year overall survival (OS) rate were the prognostic indicators evaluated by the Kaplan-Meier method. Univariate and multivariate analyses employing a Cox regression model were used to calculate hazard ratios (HRs). RESULTS: The rate of high expression of STIP1 was 55.3% (126/228) in breast cancer tissues and 14.9% (34/228) in adjacent normal tissues (χ2=81.495, P<0.001). High expression of STIP1 was associated with tumor size, stage and human epidermal growth factor receptor 2 (HER-2) status. The 5-year RFS rate was 75.4% in the STIP1 high expression group and 87.3% in the STIP1 low expression group (χ2=5.721, P=0.017). The 5-year OS rate was 84.1% in the STIP1 high expression group and 94.1% in the STIP1 low expression group (χ2=5.814, P=0.016). STIP1 was found to be an independent relapse predictor for the adjusted HR is 1.983 (95% CI, 1.031-3.815). CONCLUSIONS: High expression of STIP1 is associated with the poor prognosis of breast cancer patients and HER-2 positive expression. STIP1 may therefore serve as a prognostic biomarker for breast cancer patients.
Entities:
Keywords:
Biomarkers; breast neoplasms; stress-induced phosphoprotein 1 protein (STIP1 protein)
Authors: Julio E Celis; Pavel Gromov; Teresa Cabezón; José M A Moreira; Esbern Friis; Karin Jirström; Antonio Llombart-Bosch; Vera Timmermans-Wielenga; Fritz Rank; Irina Gromova Journal: Mol Cell Proteomics Date: 2008-07-16 Impact factor: 5.911
Authors: José Díaz-Chávez; Miguel A Fonseca-Sánchez; Elena Arechaga-Ocampo; Ali Flores-Pérez; Yadira Palacios-Rodríguez; Guadalupe Domínguez-Gómez; Laurence A Marchat; Lizeth Fuentes-Mera; Guillermo Mendoza-Hernández; Patricio Gariglio; César López-Camarillo Journal: PLoS One Date: 2013-05-27 Impact factor: 3.240
Authors: Juliet Padden; Dominik A Megger; Thilo Bracht; Henning Reis; Maike Ahrens; Michael Kohl; Martin Eisenacher; Jörg F Schlaak; Ali E Canbay; Frank Weber; Andreas-Claudius Hoffmann; Katja Kuhlmann; Helmut E Meyer; Hideo A Baba; Barbara Sitek Journal: Mol Cell Proteomics Date: 2014-07-17 Impact factor: 5.911